Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Glioblastoma 12Central Nervous System Neoplasms 11Brain Neoplasms 9Astrocytoma 8Glioma 6Oligodendroglioma 4Gliosarcoma 3Neoplasms 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1Multiple Myeloma 1Cognition Disorders 1

Interventions

Dexamethasone 20Melphalan 13Thalidomide 10Bortezomib 10Lenalidomide 8Cyclophosphamide 8Prednisone 6Filgrastim 6Doxorubicin 6Vincristine 5Epoetin Alfa 5pomalidomide 3Zoledronic Acid 3Peripheral Blood Stem Cell Transplantation 3Idarubicin 3carfilzomib 2Vorinostat 2Radiotherapy 2Interferon-alpha 2Granulocyte Colony-Stimulating Factor 2Early Intervention, Educational 2Darbepoetin alfa 2Carmustine 2Calcium Dobesilate 2Busulfan 2valspodar 1sargramostim 1oblimersen 1liposomal doxorubicin 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Plasma Cell × Lomustine × Clear all
NCT00003603 2013-09-20

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Unknown
660 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡